Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia
نویسندگان
چکیده
OBJECTIVE The objective of this study was to examine the relationship between patient beliefs about medication use and their likelihood of discontinuing treatment prematurely. Associations of patient beliefs about medication with clinical psychopathology and their life satisfaction were also assessed. METHODS This post-hoc analysis used data from a randomized, open label, 1-year trial of antipsychotics in the treatment of patients with schizophrenia or schizoaffective disorders (N = 664). Medication management including dosage adjustment and medication switching was at doctors' discretion, reflecting naturalistic treatment in usual clinical care settings. Early treatment discontinuation was defined as all-cause study drop out. Patient-reported beliefs about medication were assessed by Rating of Medication Influences (ROMI), degree of clinical psychopathology was measured by Positive and Negative Syndrome Scale (PANSS), and patient quality of life was measured by Lehman Quality of Life Interview (LQLI). RESULTS Patient perception of medication benefit was the only strong predictor of treatment duration among the 5 underlying dimensions of medication influence. Higher level of perceived beneficial effect of medication was associated with reduced risk of early treatment discontinuation (Hazard ratio = 0.56, 95% Confidence Interval [0.40, 0.79], p = 0.001). Patients with greater beliefs in the beneficial effect of treatment also had better clinical psychopathology outcome and were more satisfied with their quality of life and well-being. CONCLUSION Understanding the predictors of early treatment discontinuation in the care of schizophrenia patients is important for the development of interventions to improve treatment outcome. Current findings suggest that patient perception of beneficial effect of medication may be a critical factor in achieving treatment persistence and a satisfactory treatment outcome.
منابع مشابه
TAILOR – tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial
BACKGROUND The aim of the TAILOR trial is to investigate the effect of closely monitored tapering/discontinuation versus maintenance therapy with antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder and with minimum 3 months' remission of psychotic symptoms. METHODS AND DESIGN Two hundred and fifty patients will be included from the psychia...
متن کاملTreatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence
BACKGROUND This study aimed to improve physicians' understanding of the treatment circumstances and needs of outpatients with schizophrenia at risk of nonadherence, by naturalistically assessing antipsychotic treatment patterns, clinical outcomes, and health care service use in this little-studied patient population. METHODS In this one-year, prospective, multicenter, noninterventional, obser...
متن کاملA Randomized Clinical Trial of Group Cognitive-Rehabilitation Therapy for Patients with Schizophrenia Resistant to Medication
Objectives: Against the background of evidence-based treatments for schizophrenia resistant to medication, the implementation of cognitive-Rehabilitation therapy (CRT) becomes more important, especially about patients who don’t response to medication. There is less evidence for group format and face to face structure of CRT and also for resistant to medication patients. This research investigat...
متن کاملEvaluation of the efficacy and safety of pregabalin as an adjuvant to antipsychotics in patients with chronic schizophrenia: a six-week pilot double-blind placebo-controlled trial
Introduction and objectives: Antipsychotics or dopamine receptor antagonists are the major components of treatment but about 10-20% of patients with schizophrenia do not benefit from treatment with antidopaminergic agents, indicating other neuronal systems may be involved in this disorder (2). Dysregulation of both excitatory and inhibitory mechanisms N-Methyl-D-aspartic acid (NMDA) and γ-Amino...
متن کاملTime to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
BACKGROUND There is an ongoing debate over whether atypical antipsychotics are more effective than typical antipsychotics in the treatment of schizophrenia. This naturalistic study compares atypical and typical antipsychotics on time to all-cause medication discontinuation, a recognized index of medication effectiveness in the treatment of schizophrenia. METHODS We used data from a large, 3-y...
متن کامل